Chief Information Officer Harrison Robert Gardner of Sera Prognostics (NASDAQ:SERA) executed a sale of 716 shares of Class A common stock on March 11, 2026. The shares were transacted at a reported price of $2.04 per share, producing proceeds of $1,460. The trade was part of a block sale that recorded prices between $1.90 and $2.30.
Company filings indicate the disposition was intended to satisfy tax withholding obligations arising from the vesting of restricted stock units. After completing the sale, Gardner's direct holdings in Sera Prognostics stand at 76,712 shares.
Sera’s market price sits at $1.99 at the time of reporting, a level that represents a 51% decline over the past 12 months. The trading activity by an officer is small in dollar terms relative to the company’s overall capitalization, but it comes as the company navigates both operational and clinical news.
On the clinical front, Sera reported encouraging results from a sizable trial of its PreTRM Test, which is designed to identify pregnant women at elevated risk for spontaneous preterm birth. The study enrolled 5,018 women and demonstrated meaningful reductions in early deliveries when the blood-based test was combined with specific interventions. As published in the PREGNANCY journal, the trial showed a 56% reduction in births before 32 weeks and a 32% reduction in births before 35 weeks compared with standard prenatal care.
Interventions referenced in the study included daily vaginal progesterone and low-dose aspirin, which, when paired with the PreTRM Test, were associated with improved newborn outcomes versus the standard of care reported in the trial.
Market attention to Sera has also shifted: Jefferies has initiated coverage with a Buy rating and assigned a $5.00 price target. Separately, InvestingPro’s analysis is cited as viewing SERA as potentially undervalued at current market levels. That analysis notes the company holds more cash than debt despite continuing to burn cash, and highlights that subscribers can access Fair Value estimates along with seven additional ProTips ahead of Sera’s March 18 earnings report.
The combination of an insider sale for tax purposes, significant clinical data, and fresh analyst coverage creates a mixed information set for investors. The CFO-level sale was limited in size and was executed to meet tax obligations tied to equity vesting; meanwhile, clinical results and broker coverage provide reasons for market participants to reassess the company’s prospects ahead of the imminent earnings release.
Key points
- Harrison Robert Gardner sold 716 shares on March 11, 2026, at $2.04 per share, totaling $1,460, as part of a block trade priced between $1.90 and $2.30.
- Positive clinical trial results for the PreTRM Test in a 5,018-woman study showed a 56% reduction in births before 32 weeks and a 32% reduction before 35 weeks; results were published in the PREGNANCY journal.
- Jefferies initiated coverage of Sera Prognostics with a Buy rating and a $5.00 price target; InvestingPro analysis flags the stock as potentially undervalued ahead of the March 18 earnings report.
Risks and uncertainties
- Share price volatility: Sera’s shares have fallen 51% over the past year, reflecting market uncertainty.
- Cash burn: InvestingPro notes the company is burning through cash, a factor that can influence future financing and operational flexibility.
- Earnings-period uncertainty: Investors face the usual uncertainty ahead of the March 18 earnings release that InvestingPro references.